aTyr Pharma Inc. (LIFE)
Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution
Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Natera - Natera Announces Publication of Signatera™Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Revvity - Revvity to Present at J.P. Morgan Healthcare Conference
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
XWELL Expands Beyond Airports with New Wellness Retail Location in New York City’s Pennsylvania Station
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference